Search details
1.
Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.
Eur J Nucl Med Mol Imaging
; 2024 Jun 19.
Article
in English
| MEDLINE | ID: mdl-38896128
2.
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology.
Eur J Nucl Med Mol Imaging
; 51(5): 1383-1394, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38082196
3.
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
Eur J Nucl Med Mol Imaging
; 51(3): 749-755, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37943339
4.
Modelling the In Vivo and Ex Vivo DNA Damage Response after Internal Irradiation of Blood from Patients with Thyroid Cancer.
Int J Mol Sci
; 25(10)2024 May 17.
Article
in English
| MEDLINE | ID: mdl-38791531
5.
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.
Eur J Nucl Med Mol Imaging
; 50(12): 3765-3776, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37474735
6.
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T.
Eur J Nucl Med Mol Imaging
; 50(11): 3465-3474, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37272956
7.
Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors.
Eur J Nucl Med Mol Imaging
; 50(10): 3011-3021, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37147478
8.
Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report.
BMC Neurol
; 23(1): 398, 2023 Nov 04.
Article
in English
| MEDLINE | ID: mdl-37925427
9.
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL.
Mol Imaging
; 2022: 7056983, 2022.
Article
in English
| MEDLINE | ID: mdl-35283693
10.
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
Prostate
; 82(14): 1406-1412, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35860909
11.
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up.
Eur J Nucl Med Mol Imaging
; 49(12): 4262-4270, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35650263
12.
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.
Eur J Nucl Med Mol Imaging
; 49(11): 3938-3949, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35556160
13.
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
Eur J Nucl Med Mol Imaging
; 49(13): 4727-4735, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35852555
14.
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
; 49(9): 3269-3276, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35243517
15.
Adrenal functional imaging - which marker for which indication?
Curr Opin Urol
; 32(6): 585-593, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-36081395
16.
[Theranostics for Well and Moderately Differentiated GEP-NEN]. / Theranostics bei gut bis mäßig differenzierten GEP-NEN.
Zentralbl Chir
; 147(3): 249-255, 2022 Jun.
Article
in German
| MEDLINE | ID: mdl-35705086
17.
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC.
Eur J Nucl Med Mol Imaging
; 48(8): 2566-2572, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33452632
18.
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy.
Eur J Nucl Med Mol Imaging
; 48(6): 2024-2030, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33336265
19.
Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience.
Eur J Nucl Med Mol Imaging
; 49(1): 301-310, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34215922
20.
CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection.
Eur J Nucl Med Mol Imaging
; 50(1): 228-229, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35953728